Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0041-1345(02)04041-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Identifying Promising Immunomodulators for Type 1 Diabetes (T1D) and Islet Transplantation.
J Diabetes Res
December 2024
Department of Biomedical Sciences, Heritage College of Osteopathic Medicine, Ohio University, Athens, Ohio, USA.
Type 1 diabetes (T1D) is an autoimmune chronic disorder that damages beta cells in the pancreatic islets of Langerhans and results in hyperglycemia due to the loss of insulin. Exogenous insulin therapy can save lives but does not stop disease progression. Thus, an effective therapy may require beta cell restoration and suppression of the autoimmune response.
View Article and Find Full Text PDFHumanized anti-CD25 monoclonal antibody replaces methotrexate as acute graft-versus-host disease prophylaxis in haploidentical allogeneic haematopoietic stem cell transplantation.
Br J Haematol
December 2024
Institute of Hematology, Union Hospital, Tongji Medicine College, Huazhong University of Science and Technology, Wuhan, China.
Acute graft-versus-host disease (aGVHD) significantly affects quality of life and outcomes in patients post-haploidentical haematopoietic stem cell transplantation (haplo-HSCT). Methotrexate (MTX) is commonly used to prevent aGVHD but can lead to complications like delayed haematological recovery and oral mucositis (OM). This study investigates the efficacy of anti-CD25 monoclonal antibody (mAb) as a potential MTX alternative.
View Article and Find Full Text PDFDihydroberberine alleviates Th17/Treg imbalance in premature ovarian insufficiency mice via inhibiting Rheb/mTOR signaling.
Mol Med
October 2024
Fujian Maternity and Child Health Hospital College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University, No. 18, Daoshan Road, Fuzhou, 350001, Fujian Province, China.
Background: Premature ovarian insufficiency (POI) is an immune-related condition. Dihydroberberine (dhBBR) plays a regulatory role in maintaining the T-helper 17 (Th17)/regulatory T (Treg) cell balance. This study aimed to explore the action mechanisms of dhBBR on POI.
View Article and Find Full Text PDFThe Major Role of T Regulatory Cells in the Efficiency of Vaccination in General and Immunocompromised Populations: A Review.
Vaccines (Basel)
August 2024
Department of Urology, The University of Toledo College of Medicine and Life Sciences, Toledo, OH 43614, USA.
Article Synopsis
- Vaccines have played a crucial role in controlling pandemics since the smallpox vaccine, including the recent COVID-19 outbreak, by activating various immune cells like CD4 and CD8 T cells and B cells.
- Research shows that specific T regulatory cells, like Treg and Tr1, influence how effective vaccines are, especially for immunocompromised individuals.
- Strategies to enhance vaccine efficacy include adjusting dosages, changing administration routes, giving booster shots, and using monoclonal antibodies to minimize Treg activity and stimulate stronger immune responses.
[Short-term substitution of calcineurin inhibitors (CNI) with recombinant humanized anti-CD25 monoclonal antibody (Basiliximab) as aGVHD prophylaxis in CNI intolerant patients after allogeneic hematopoietic stem cell transplantation].
Zhonghua Xue Ye Xue Za Zhi
February 2024
Department of Hematopoietic Stem Cell Transplantation, Shanghai Zhaxin Traditional Chinese and Western Medicine Hospital, Shanghai 200040, China.
To investigate the efficacy of short-term substitution of recombinant humanized anti-CD25 monoclonal antibody (Basiliximab) as acute GVHD (aGVHD) prophylaxis in calcineurin inhibitors (CNI) intolerant patients following allogeneic hematopoietic stem cell transplantation (allo-HSCT) . This study included 17 patients with refractory malignant hematological disorders who underwent salvage allo-HSCT at the Bone Marrow Transplantation Department of Shanghai Zhaxin Traditional Chinese and Western Medicine Hospital from August 2021 to August 2022 and were treated with Baliximab to prevent aGVHD due to severe adverse reactions to CNI. There were seven men and ten women, with a median age of 43 years (18-67).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!